Evaluation of single-use tangential flow filtration technology for purification of activated polysaccharides used in conjugate vaccine manufacturing.


Journal

Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292

Informations de publication

Date de publication:
11 2021
Historique:
revised: 19 08 2021
received: 07 07 2021
accepted: 24 08 2021
pubmed: 31 8 2021
medline: 26 3 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

Over the past decade, single-use tangential flow filtration (TFF) technologies have emerged to reduce system preparation time, promote fast and flexible product change over, and ultimately shorten process development and manufacturing time/cost. In this study, the performance of a recently developed Pellicon® single-use TFF capsule was compared against traditional Pellicon® cassettes by assessing TFF process performance (such as flux, residuals clearance, and yield) and post-purification product attributes (such as concentration and mass-weighted average molecular weight). Good scaling was shown by comparing process performance and product attributes across different scales and formats. Additionally, similar TFF process performance and post-purification product attributes were observed for the single-use capsule compared to the reusable TFF cassettes. The capsule requires a smaller flush than the cassette, and it is easier to use since it does not require a compression holder or pre-sanitization. The results provide insight into the application of the single-use TFF capsule and scalability of TFF processes for the purification of conjugate vaccines.

Identifiants

pubmed: 34459567
doi: 10.1002/btpr.3204
pmc: PMC9285785
doi:

Substances chimiques

Polysaccharides 0
Vaccines, Conjugate 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3204

Informations de copyright

© 2021 Pfizer Inc and EMD Millipore Corporation. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.

Références

Expert Rev Vaccines. 2002 Oct;1(3):399-410
pubmed: 12901578
Biotechnol Prog. 2016 Nov;32(6):1531-1538
pubmed: 27673326
Biotechnol Bioeng. 2019 Mar;116(3):591-597
pubmed: 30450582
Biotechnol Prog. 2021 Nov;37(6):e3204
pubmed: 34459567

Auteurs

Seyed Pouria Motevalian (SP)

Bioprocess Research and Development, Pfizer Inc., Andover, Massachusetts, USA.

Jonathan Steen (J)

Ultrafiltration Research and Development, MilliporeSigma, Bedford, Massachusetts, USA.

Janine De Leon (J)

Bioprocess Research and Development, Pfizer Inc., Andover, Massachusetts, USA.

Verl Sriskanda (V)

Analytical Research and Development, Pfizer Inc., Andover, Massachusetts, USA.

Ivette Carino (I)

Bioprocess Research and Development, Pfizer Inc., Andover, Massachusetts, USA.

Amar S Prashad (AS)

Bioprocess Research and Development, Pfizer Inc., Andover, Massachusetts, USA.

Brenda Carrillo Conde (B)

Bioprocess Research and Development, Pfizer Inc., Chesterfield, Missouri, USA.

Bo Arve (B)

Bioprocess Research and Development, Pfizer Inc., Chesterfield, Missouri, USA.

Articles similaires

Animals Flax Chickens Dietary Supplements Endo-1,4-beta Xylanases
Humans Streptococcus pneumoniae Pneumococcal Infections Serogroup Asia, Southeastern
Humans Male Netherton Syndrome Female Pneumococcal Vaccines
Transformation, Genetic Plants, Genetically Modified Agrobacterium Biolistics Protoplasts

Classifications MeSH